Celeris Corporation provides specialty clinical research to pharmaceutical, medical device and biotechnology manufacturers. For the six months ended 6/99, revenues rose 58% to $4.3 million. Net loss from continuing operations totalled $2.2 million, up from $64 thousand. Revenues reflect expanded service capabilities and a higher
volume of consulting services performed. Loss reflects higher general and administrative expenses associated with the expanded service offerings.
....
Celeris is threatened by delisting because their market cap is too small for the nasdaq it is under $4Millions.
People, do a good work. Let's bring this puppy to $2 and over and spare it the delisting.
No secret: CLRS has around $9 Millions, or nearly $3 in CASH, and little debt. Their net equity is at $9.4MM. For the 9 months they posted $6.6MM revenues and a gross profit of 2.1MM
Can you imagine buying $3 cash for $1 ??? |
